Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by IGC Pharma, Inc.
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
November 25, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
September 18, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
September 04, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Announces Results of its 2024 Annual Stockholders Meeting
August 26, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
August 22, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Reports First Quarter Fiscal 2025 Results
August 08, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
July 18, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
July 09, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
June 25, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
June 24, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
June 18, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
June 10, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
April 16, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Adds Advisor in Artificial Intelligence
April 09, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
March 20, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
March 20, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
March 12, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
February 28, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
February 23, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Reports Third Quarter Fiscal 2024 Results
February 16, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
February 01, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
January 23, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial
January 17, 2024
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s
December 19, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
December 13, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
December 06, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
November 21, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Reports Second Quarter Fiscal 2024 Results
November 13, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy
October 19, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
IGC Announces Results of its 2023 Annual Stockholders Meeting
August 21, 2023
From
IGC Pharma, Inc.
Via
Business Wire
Tickers
IGC
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today